Following in the footsteps of making Metrogel 1% available in a pump, Galderma has announced that Mirvaso Gel is now available in a pump dispenser. Previously Galderma has claimed the benefits of a pump over a tube include – better looking dispenser, minimizing waste, easier compliance with prescribing instructions and “facilitating product handling”.
Galderma Press Release
Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea
New Pump Delivery System Dispenses a Consistent Dose at Each Use
May 19, 2016 09:00 AM Eastern Daylight Time
FORT WORTH, Texas. Galderma Laboratories, L.P., a global leader focused on medical treatment options in dermatology and skin health and the maker of Cetaphil, today announced the availability of a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33%* for the treatment of the persistent facial redness associated with rosacea.
The Mirvaso Gel Pump is now available by prescription to patients in pharmacies nationwide. The improved delivery system of the Mirvaso Gel Pump dispenses a consistent dose at each use.
“The availability of the Mirvaso Gel Pump offers a number of benefits to patients with facial erythema,” said Dr. Sandra Johnson, board-certified dermatologist at Johnson Dermatology in Fort Smith, Arkansas and Galderma consultant.
“Research proves that the majority of patients prefer a pump dispenser over a tube. As a frequent prescriber of Mirvaso Gel, I am excited for the introduction of this dosing option that is convenient to use for my patients.”